RATIO-SUMATRIPTAN TABLET

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE)

Fáanlegur frá:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC númer:

N02CC01

INN (Alþjóðlegt nafn):

SUMATRIPTAN

Skammtar:

100MG

Lyfjaform:

TABLET

Samsetning:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 100MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

6/30

Gerð lyfseðils:

Prescription

Lækningarsvæði:

SELECTIVE SEROTONIN AGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0123238001; AHFS:

Leyfisstaða:

CANCELLED POST MARKET

Leyfisdagur:

2010-08-02

Vara einkenni

PRODUCT MONOGRAPH
Pr
ratio-SUMATRIPTAN
(Sumatriptan Succinate Tablets)
25 mg, 50 mg and 100 mg Sumatriptan
5-HT
1
Receptor Agonist
Migraine Therapy
ratiopharm inc.
Date of Preparation:
Canada, J7J 1P3
September 22, 2005
Control #: 101202
PRODUCT MONOGRAPH
Pr
ratio-SUMATRIPTAN
(Sumatriptan Succinate Tablets)
25 mg, 50 mg and 100 mg Sumatriptan
THERAPEUTIC CLASSIFICATION
Migraine Therapy
PHARMACOLOGIC CLASSIFICATION
5-HT
1
Receptor Agonist
CLINICAL PHARMACOLOGY
Sumatriptan succinate has been shown to be effective in relieving
migraine headache. It is an agonist for a
vascular 5-hydroxytryptamine
1D
(5-HT
1D
) receptor subtype (a member of the 5-HT
1
family), and has only
weak affinity for 5-HT
1A
receptors and no significant activity (as measured using standard
radioligand
binding assays) or pharmacological activity at 5-HT
2
, 5-HT
3
, 5-HT
4
, 5-HT
5A
, or 5-HT
7
receptor subtypes,
or at alpha
1
-, alpha
2
-, or beta-adrenergic; dopamine, or dopamine
2
; muscarinic; or benzodiazepine
receptors.
The therapeutic activity of sumatriptan succinate in migraine is
generally attributed to its agonist activity
at 5-HT
1B
/5-HT
1D
receptors. Two current theories have been proposed to explain the
efficacy of 5-HT
1
receptor
agonists
in
migraine.
One
theory
suggests
that
activation
of
5-HT
1
receptors
located
on
intracranial blood vessels, including those on the arteriovenous
anastomoses, leads to vasoconstriction,
which is believed to be correlated with the relief of migraine
headache. The other hypothesis suggests that
activation of 5-HT
1
receptors on perivascular fibres of the trigeminal system results in
the inhibition of
pro-inflammatory neuropeptide release. These theories are not mutually
exclusive.
Experimental data from animal studies shows that sumatriptan succinate
also activates 5- HT
1
receptors
on peripheral terminals of the trigeminal nerve which innervates
cranial blood vessels. This causes the
inhibition of neuropeptide release. It is thought that such an action
may contribute to the anti-migraine
3
action